Global Laryngeal Cancer Therapeutics Market 2019-2023 – Advent of Novel Therapies | Technavio

Preference for treatment using therapeutics will drive market growth in North America

LONDON--()--Technavio’s report on the laryngeal cancer therapeutics market is expected to grow by $720.06 million during 2019-2023. The increase in smoking and the consumption of tobacco products has resulted in the increasing incidence of laryngeal cancer. Moreover, there is also an increase in the incidence of HPV-caused cancers. The high mortality rate and the growing prevalence of the indication are leading to a rise in the use of therapeutics such as chemotherapy and targeted therapy for the treatment. Read More

Laryngeal Cancer Therapeutics Market: Advent of Novel Therapies are Adding Significant Value to the Market Growth

The increasing prevalence of laryngeal cancer and the high mortality rate have led to the development of more advanced therapies for the treatment of the disease. The market has witnessed an increase in the research of novel therapeutics such as targeted therapies, biologics, and regenerative therapies for laryngeal cancer. Advancements in the research of these novel therapies are expected to add significant value to the growth of the laryngeal cancer therapeutics market in the coming years.

Get a free sample analysis from the Laryngeal Cancer Therapeutics Market

Laryngeal Cancer Therapeutics Market: Late-Stage Pipeline is a Positive Sign for Market Growth

There are several pharmaceutical vendors operating in the market with novel therapies for the treatment of various types of head and neck cancers, including laryngeal cancer. Vendors have actively been researching targeted therapies such as PD-1 and EGFR inhibitors. As a result, the pipeline of these targeted therapies for laryngeal cancer is growing strong, with highly promising treatments in the late stages of clinical trials. This is a positive sign for the growth of the market during the forecast period.

The North American region is dominating the global laryngeal cancer therapeutics market, with a market share of close to 42%. The growth in the region is attributed to increasing preference for the treatment using therapeutics for various head and neck cancer, including laryngeal cancer.

Major vendors covered in the laryngeal cancer therapeutics market are Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., and Sanofi.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Related Reports on Healthcare are:

  1. Global Fallopian Tube Cancer Therapeutics Market 2019-2023
  2. Global Blood Cancer Therapeutics Market 2019-2023
  3. Global Cervical Cancer Diagnostic Testing Market 2019-2023

Email us at media@technavio.com or register online for a brochure and synopsis

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

Technavio is an international consulting and market research firm dedicated to empowering confident strategic decisions within the medical device, dental, pharmaceutical, and more Healthcare industries.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com

Release Summary

Technavio’s report on the laryngeal cancer therapeutics market is expected to grow by $720.06 million during 2019-2023.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com